Drug intelligence / Profile preview

pirmitegravir

Development stage: Phase 2
Lead developer: ST Pharm
Modality: Small Molecules
Administration: Oral (inferred Based On Class And Typical Administration Route)

Overview

Pirmitegravir (STP0404) is a small molecule HIV-1 integrase inhibitor under investigation for the treatment of human immunodeficiency virus (HIV) infection. It acts by inhibiting the activity of HIV integrase, an enzyme essential for viral replication, thereby blocking the integration of viral DNA into the host genome. Pirmitegravir is chemically distinct from other approved integrase inhibitors and has been developed as a potential new therapy for HIV infection[6]. Its molecular formula is C27H31ClN4O3 and it has a molecular weight of 495.01 g/mol.

Other names: 2245231-10-9

Targets

Integrase allosteric pocket (HIV)

Beyond the preview

Go deeper on pirmitegravir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pirmitegravir.

Explore the full profile